Highest-materiality recent filing
Synlogic confirms Nasdaq delisting, will trade on OTCQB as public shell
Withdrew Nasdaq hearing on Jan 16, 2026; shares suspended Jan 21, 2026.
Synlogic withdraws Nasdaq hearing; shares suspended Jan 21, will move to OTC Markets
Synlogic withdrew its Nasdaq hearing request on Jan 16, 2026, after being deemed a public shell.
Nasdaq notifies Synlogic it is a public shell; delisting possible unless hearing succeeds
Nasdaq Staff believes Synlogic is a public shell, citing zero revenue, minimal R&D costs, and reduced operations since Feb 2024.
Antoine Awad's employment ends Dec 31, 2024; receives $218,856 lump-sum (6 months salary) plus $246,213 retention bonus.
Synlogic posts Q3 net loss of $0.1M, cash $19.4M; evaluating strategic options
Net loss of $0.1M ($0.01 per share) vs $12.1M ($2.57 loss per share) in Q3 2023.
Synlogic reports Q2 net income $2M on restructuring gain; exploring strategic options
Cash and equivalents $20.0M as of June 30, 2024.
Synlogic posts Q1 net loss of $31.6M; retains advisor to explore strategic alternatives
Retained Lucid Capital Markets to evaluate acquisition, merger, or other strategic transaction.
Synlogic discontinues PKU program; Q4 net loss $14.5M, cash $47.7M
Discontinued Synpheny-3 pivotal study of SYNB1934 for PKU; evaluating strategic options.
Synlogic CEO Aoife Brennan to depart March 9; COO Antoine Awad to leave May 30
CEO Dr. Aoife Brennan's employment ends March 9, 2024; receives $628,305 severance (12 months base).
Rights plan triggered at 15% ownership (20% for passive institutional investors); expires Feb 20, 2025.
Synpheny-3 study of SYNB1934 for PKU discontinued; internal data review found it unlikely to meet primary endpoint; safety acceptable.
Synlogic Q3 net loss narrows to $12.1M; cash runway extended into H1 2025
Net loss of $12.1M ($2.57 per share) vs $17.9M ($3.73) in Q3 2022; revenue $0.4M from Roche collaboration.
Synlogic raises $21M in public offering, funds PKU Phase 3 and manufacturing
Gross proceeds of $21M from 7.39M shares and 7.39M warrants at $2.84 per unit.
Reverse stock split at 1:15 ratio effective 5:00 PM ET on Sep 27, 2023; shares outstanding reduce from ~69M to ~4.6M.
Synlogic and Roche amend collaboration; IBD option deadline extended to Jan 15, 2024 or later
Roche holds exclusive option to negotiate a license for Synlogic's IBD Synthetic Biotic medicine.
Synlogic reports Q2 2023 net loss of $15.0M; Phase 3 PKU trial initiated
Net loss $15.0M ($0.21/sh) vs $15.8M ($0.22/sh) in Q2 2022; cash $46.3M.
Synlogic initiates Phase 3 PKU study SYNB1934, cuts workforce 21%
Initiated Synpheny-3 global pivotal Phase 3 trial of SYNB1934 for phenylketonuria (PKU), targeting ~150 patients.
Synlogic Q1 net loss $15.6M; cash $57.4M; PKU program gets FDA/EMA designations
Net loss of $15.6M ($0.23 per share) vs $15.7M in Q1 2022; revenue flat at $0.2M.
Synlogic reports Q4 2022 net loss $16.7M; PKU Phase 3 on track for H1 2023
Q4 2022 net loss $16.7M ($0.24/share) vs $15.1M ($0.21) in Q4 2021; full year net loss $66.1M ($0.92/share).
SYNB8802 reduced urinary oxalate by 38% vs placebo at 3x10^11 TID dose in Roux-en-Y gastric bypass patients.
Synlogic receives Nasdaq delisting notice over sub-$1 bid price
Nasdaq notified Synlogic on Dec 6, 2022, that bid price was below $1.00 for 30 consecutive business days.
Synlogic: SYNB1353 achieves proof of mechanism in HCU; cuts workforce 25%
SYNB1353 reduced plasma methionine AUC by -24.8% and -26.2% at 1x10^12 dose vs placebo -2.1% in Phase 1.
Cash, cash equivalents and short-term investments of $91.7M as of Sept 30, 2022; runway into 2024.
Synlogic reports positive Phase 2 PKU data; SYNB1934 advances to Phase 3 in H1 2023
Phase 2 Synpheny-1 study met primary endpoint: 60% response rate with 42% mean Phe reduction among responders.
Synlogic achieves second research milestone under Roche IBD collaboration
Second pre-specified milestone earned; milestone payment triggered under Roche collaboration.
Synlogic Q2 2022 net loss $15.8M; cash $106.8M funds into 2024; three data readouts in H2 2022
Net loss $15.8M ($0.22 per share) vs $14.5M ($0.28) in Q2 2021; revenue $0.2M from Roche IBD collaboration.
Synlogic reports Q1 net loss of $15.7M; cash $120.5M supports runway into 2024
Net loss of $15.7M ($0.22/share) vs $15.0M ($0.36/share) in Q1 2021.
Synlogic Q4 2021 net loss $15.1M; cash $136.6M; PKU Phase 3 on track for H2 2022
Q4 2021 net loss $15.1M ($0.21/share) vs $14.6M ($0.39/share) in Q4 2020; FY 2021 net loss $60.6M ($1.09/share).
Synlogic appoints Michael Jensen as CFO effective March 3, 2022
Michael Jensen named CFO; previously CFO at Intrinsic Therapeutics and Taconic Biosciences.
Synlogic reports Q3 net loss $16M; PKU Phase 2 shows proof of concept, moving to Phase 3
Interim Phase 2 SynPheny-1 data: SYNB1618 achieved proof of concept with statistically significant Phe reduction in PKU patients.
SYNB1353 is an investigational Synthetic Biotic medicine for homocystinuria (HCU), developed using Synlogic's platform and Ginkgo's codebase.
Synlogic prices $45M public offering of 15M shares at $3.00 per share
Priced underwritten public offering of 15 million shares of common stock at $3.00 per share.
Synlogic reports positive PKU data: SYNB1618 reduces Phe, SYNB1934 shows 2x activity
SYNB1618 showed 20% reduction in fasting plasma Phe after 14 days at 1e12 dose in Phase 2 SynPheny-1 interim analysis.
Cash, equivalents, and investments of $115.5M as of June 30, 2021; runway into second half of 2023.
On February 20, 2025, Michael Heffernan tendered his resignation as a member of the board of directors (the “Board”) of Synlogic, Inc. (the “Company”) and as a member of the audit committee and nominating and governance committee of the Board, effective immediately.
On January 10, 2025, Nick Leschly tendered his resignation as a member of the board of directors (the “Board”) of Synlogic, Inc. (the “Company”) and as a member of the compensation committee of the Board, effective immediately.
On March 20, 2024, Patricia N. Hurter, Ph.D. notified the Board of her decision to resi
On March 20, 2024, Mike Burgess, MB, CHB, Ph.D notified the Board of his decision to resign from the Board and the Audit Committee and the Science and Technology Committee, effective immediately.
On March 20, 2024, Lisa Kelly-Croswell notified the Board of her decision to resign from the Board and the Compensation Committee as well as the Nominating and Governance Committee, effective immediately.
appointed James Flynn effective March 19, 2024 (the “Effective Date”), as a director to the Board to serve as a Class I Director
Synlogic, Inc. (the “ Company ”) and Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, agreed that Dr. Brennan’s employment with the Company will terminate effective March 9, 2024
Mr. Awad’s employment with the Company will end on May 30, 2024
Dr. Brennan also resigned from the Company’s Board of Directors, effective March 9, 2024.
the Company and Aoife Brennan, M.B. Ch.B., the Company’s President and Chief Executive Officer, agreed on February 8, 2024 that Dr. Brennan’s employment with the Company will terminate effective as of March 9, 2024.
On November 13, 2023, Michael Jensen, Chief Financial Officer of Synlogic, Inc. (the “Company”) resigned from his role as Chief Financial Officer of the Company, effective December 1, 2023 (the “Departure Date”).
On March 3, 2022, Synlogic, Inc. (the “Company”) announced the appointment of Michael Jensen as Chief Financial Officer, effective March 3, 2022.
Max materiality 1.00 · Median 0.65 · Most common event other_material